Increased serum neopterin concentrations in patients with Alzheimer's disease

Clinical Chemistry and Laboratory Medicine

Volumn 37, Issue 4, 1999, Pages 429-431

  Leblhuber, Friedrich ^a   Walli, Johannes ^a   Demel, Ulrike ^b   Tilz, Gernot P ^b   Widner, Bernhard ^c   Fuchs, Dietmar ^c,d  

^a Abteilung fur Gerontologie   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c Institut for Theoretische Physik Universitat of Innsbruck   (Austria)

^d UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Alzheimer's disease; Neopterin; Peripheral immune activation

Indexed keywords

INTERLEUKIN 2 RECEPTOR; NEOPTERIN; TUMOR NECROSIS FACTOR RECEPTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MENTAL HEALTH; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; HUMANS; MALE; NEOPTERIN;

EID: 0032919337     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1999.070     Document Type: Article

References (31)

1. Mooradian AD, Reed RL, Scuderi P. Serum levels of tumor necrosis factor alpha, interleukin-1 alpha and beta in healthy elderly subjects. Age 1991; 14:61-4.
2. Lopez OL, Rabin BS, Huff FJ. Serum autoantibodies in Alzheimer's disease. Acta Neurol Scand 1991; 84:441-4.
3. Araga S, Kagimoto H, Funamoto K, Takahashi K. Reduced natural killer cell activity in patients with dementia of the Alzheimer type. Acta Neurol Scand 1991; 84:259-63.
4. Pirtilla T, Mattinen S, Frey H. The decrease of CD8-positive lymphocytes in Alzheimer's disease J Neurol Sci 1992; 107:160-5.
5. Geldmacher DS, Whitehouse PJ. Evaluation of dementias. N Engl J Med 1996; 335:30-6.
6. Abraham RF, Selkoe DJ, Potter H. Immunochemical identification of the serine protease inhibitor alphal-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988; 52:487-501.
7. Rozemuller JM, Stam FC, Eikelenboom P. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease. Neurosci Lett 1990; 119:75-8.
8. Duguid, JR, Bohmont CW, Liu N, Tourtelotte WW. Changes in brain gene expression shared by scrapie and Alzheimer's disease. Proc Natl Acad Sci USA 1989; 86:7260-4.
9. Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A. On the cellular source and function of interleukin-6 produced in the central nervous system. Eur J Immunol 1989; 19:689-94.
10. Bauer J, Strauss S, Volk B, Berger M. IL-6-mediated events in Alzheimer's disease pathology. Immunol Today 1991; 12:422.
11. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994; 344:796-8.
12. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995; 38:357-66.
13. Blass JB. Pathophysiology of the Alzheimer's syndrome. Neurology 1993; 43 (Suppl 4): 25-38.
14. Shalit F, Sredni B, Brodie C, Kott E, Huberman MT. Lymphocyte subpopulations and activation markers correlate with severity of Alzheimer's disease. Clin Immunol Immunopathol 1995; 75:246-50.
15. Leblhuber F, Walli J, Tilz GP, Wachter H, Fuchs D. Systemische Immunsystemveränderungen bei Patienten mit Alzheimer'scher Demenz. Dtsch Med Wochenschr 1998; 123:787-91.
16. Fuchs D, Weiss G, Wachter H. Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int Arch Allergy Immunol 1993; 101:1-6.
17. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 1988; 9:150-5.
18. McKhann G, Drachmann D, Folstein M, Katzmann R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force of Alzheimer's disease. Neurology 1994; 34:943-4.
19. Ikeda T, Yamamoto K, Kaneyuki H, Yamada M. Interleukin-2 receptor in peripheral blood lymphocytes of Alzheimer's disease patients. Acta Psychiatr Scand 1991; 84:262-5.
20. Singh VK. Neuroautoimmunity: pathogenic implications for Alzheimer's disease. Gerontology 1997; 43:79-94.
21. Shahabuddin, S. Expression and release of IL-2 receptor and production of IL-2 by activated T-lymphocyte subsets. J Clin Lab Immunol 1991; 36:27-32.
22. Leblhuber F, Walli J, Jellinger K, Tilz GP, Widner B, Laccone F, Fuchs D. Activated immune system in patients with Huntington's disease. Clin Chem Lab Immunol 1998; 36:747-50.
23. Leblhuber F, Walli J, Tilz GP, Jellinger K, Wachter H, Fuchs D. Increased serum neopterin concentrations in a patient with Creutzfeld-Jacob disease. J Neurol Neurosurg Psych 1996; 10:138-9.
24. Hampel H, Muller-Spahn F, Berger C, Haberl A, Ackenheil M, Hoch C. Evidence of blood-cerebrospinal fluid impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. Dementia 1995; 6:349-54.
25. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psych 1994; 151:1105-13.
26. Singh VK. Immune activation model in Alzheimer disease. Mol Chem Neuropathol 1996; 28:105-11.
27. Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Ageing 1996; 17:681-6.
28. Rich BJ, Rasmusson DX, Folstein NF, Carson RA, Kawas C, Brandt J. Nonsteoridal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995; 45:51-5.
29. Frecker MF, Pryse-Phillips WE, Strong HR. Immunological associations in familial and non-familial Alzheimer patients, and their families. Can J Neurol Sci 1994; 21:112-9.
30. Singh VK. Immune activation model in Alzheimer's disease. Mol Chem Neuropathol 1996; 28:105-11.
31. Fuchs D, Malkovsky M, Reibnegger G, Werner ER, Forni G, Wachter H. Endogenous release of interferon-gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation. Immunol Lett 1989/90; 23:103-8.